Podcast: Play in new window | Download | Embed
Clinical research in eye care is evolving and it is no longer limited to universities or large pharmaceutical companies. In this conversation, Dr. Chris Lievens sits down with Dr. Brad Hall to explore how everyday eye care professionals can play a meaningful role in advancing research, improving patient care, and contributing to the future of the profession.
Dr. Brad Hall is the founder of Sengi Clinical, a clinical research organization focused on investigator-initiated trials in eye care. With over a decade of experience in clinical research and involvement in dozens of studies and publications, he has built a career around helping clinicians bridge the gap between clinical practice and scientific discovery. His work centers on making research more accessible, practical, and actionable for eye care professionals—especially those in private practice who may not traditionally see themselves as researchers.
This conversation highlights a powerful shift happening in the profession: clinicians are no longer just participants in research—they are becoming leaders of it. Through real-world data, practical insights, and a growing number of accessible tools, eye care professionals now have the opportunity to shape the future of care from within their own practices.
Topics Covered :
From Observer to Contributor
Many clinicians associate research with large, sponsor-driven trials—studies funded and controlled by pharmaceutical or medical device companies. In these traditional models, the sponsor designs the study, owns the data, and determines publication outcomes.
However, Dr. Hall highlights a powerful alternative: investigator-initiated trials (IITs). These allow eye care professionals to take ownership of the entire research process—from asking the question to publishing the results.
This shift is significant. Instead of simply participating in research, clinicians can now lead it. That means generating insights based on real patient populations, real workflows, and real-world challenges.
Why Real-World Data Matters
One of the most compelling points discussed is the difference between controlled studies and real-world application. Sponsored trials often operate within strict protocols and narrow patient criteria. While this produces high-quality data, it does not always reflect how treatments perform in everyday practice.
Investigator-led research, on the other hand, captures what actually happens in the clinic. Patients may not follow protocols perfectly, and outcomes may vary—but that variability is valuable. It provides insight into how treatments perform outside of ideal conditions.
For eye care professionals, this means research can directly inform better patient care—not just theoretical outcomes.
Getting Started: Lowering the Barrier
A common misconception is that clinical research is too complex or resource-intensive for private practice. While research does require structure and planning, Dr. Hall emphasizes that there are accessible entry points.
One of the best starting places is retrospective research—analyzing data that already exists within a practice. Clinicians are often sitting on a “gold mine” of patient data that can be used to answer meaningful clinical questions.
This approach reduces cost, simplifies logistics, and builds foundational experience that can later support larger studies.
Avoiding Common Pitfalls
While the opportunity is exciting, there are critical steps that cannot be overlooked. One of the most important is obtaining ethics approval through an Institutional Review Board (IRB). Skipping this step can invalidate an entire study and prevent publication.
Similarly, prospective studies must be registered in clinical trial databases before enrolling patients. Missing this step can lead to outright rejection from journals.
These are not minor details—they are foundational requirements. Success in research depends not just on the idea, but on executing the process correctly.
Time, Flexibility, and Investment
Clinical research requires more than interest—it requires commitment. Clinicians must evaluate whether they have:
- Dedicated time for study design and oversight
- Flexible scheduling to accommodate patient visits
- Financial resources or access to funding
Prospective studies, in particular, can cost tens of thousands of dollars or more, making partnerships with industry sponsors an important consideration.
The Future of Clinical Research in Eye Care
Perhaps the most exciting part of this conversation is what lies ahead. Advances in technology are making research more accessible than ever.
From AI-assisted literature reviews to fully remote clinical trials with electronic consent and at-home testing, the barriers to entry are rapidly decreasing.
This opens the door for private practices to become innovation hubs—contributing meaningful data without the traditional constraints of large institutions.
